OXiGENE, Inc. is a biopharmaceutical company whose mission is finding (via discovery or in-licensing) and developing new and improved therapeutics that deliver significant medical benefits to patients with cancer and sight-threatening eye diseases and conditions.
Dr. Langecker was named Chief Development Officer in 2009, and has more than 20 years of experience in successfully developing both drugs and biological products. Among the approved oncology drugs he has had a role in developing are FORMESTAN®, LENTARON®, TEMODAL®, INTRON-A® for adjuvant treatment of melanoma, EULEXIN® and BEXXAR®. Dr. Langecker joins OXiGENE from DURECT Corporation where he served as Chief Medical Officer. He received his medical degree and his doctorate in medical sciences from the Ludwig-Maximilians University in Munich and trained in hematology and oncology. Dr. Langecker was formerly based in Switzerland where he supported development of early aromatase inhibitors and worked on a variety of other products for CIBA GEIGY (now Novartis). His industry experience in the United States includes key roles with Schering-Plough, Coulter Pharmaceuticals, SUGEN, Inc., and Intarcia Therapeutics.
Barbara Riching, CPA
Chief Financial Officer
Barbara Riching, CPA, has served as Chief Financial Officer since July 2012. She joined the company in December 2011 as Director of Finance. Ms. Riching has more than 20 years of experience in senior accounting and financial management positions in publicly traded pharmaceutical, biotechnology and retail companies. She served as Senior Director of Finance at Abgenix, Inc., (acquired by Amgen, Inc.) where she was responsible for all finance activities, including SEC reporting, cash management, investing, forecasting and helping with multiple financings. Prior to Abgenix, she served as Director of Accounting at ALZA Corporation where she managed accounting operational areas. Earlier positions included Director of Finance and Controller at Natural Wonders a retail chain of over 200 stores and Audit Manager at Ernst & Young. She holds a B.A. from the University of California, Santa Barbara in economics, with an accounting emphasis, and is a Certified Public Accountant in California.
Mr. Driscoll has more than 30 years of senior level financial and operational management experience in both private and public companies in the biotechnology and diagnostic healthcare sectors. Most recently, he served as Chief Financial Officer at Novavax, a Nasdaq based vaccine company. Prior to that, he served as Chief Financial Officer and became Chief Executive Officer at Genelabs prior to the company’s acquisition by GlaxoSmithKline. In addition, Mr. Driscoll was employed by OXiGENE, Inc., initially as Chief Financial Officer and subsequently as Chief Executive Officer. Mr. Driscoll has also served in senior financial positions at Collagenesis, Inc. and Instrumentation Laboratory. Mr. Driscoll has been involved in a number of equity- based financings that have raised in excess of $300 million, the award of major government research contracts and M&A transactions.
David J. Chaplin, Ph.D
Dr. Chaplin formerly served as chief scientific officer and head of research and development at OXiGENE, and more recently has been a scientific advisor to the company. Dr. Chaplin has more than 30 years in oncology research and drug development. He has been a leader in the field of vascular targeting and was the original discoverer of the vascular disrupting action of Combretastatin (ZYBRESTAT®). His original work formed the basis for not only the development of ZYBRESTAT with OXiGENE, but also the subsequent vascular targeting development programs at AstraZeneca and Aventis. Dr. Chaplin has more than 18 years of experience in oncology research. Prior to his association with OXiGENE, Dr. Chaplin was Vice President, Oncology at Aventis Pharma in Paris. Before the merger of Rhone Poulenc Rorer (RPR) with Hoechst Marion Roussell, Dr. Chaplin was Senior Director of Oncology at RPR from 1998 to 1999. From 1992 to 1998, Dr. Chaplin led the Cancer Research Campaign's (CRC) Tumor Microcirculation Group, based at the Gray Laboratory Cancer Research Trust, Mount Vernon Hospital, London. Dr. Chaplin has also served as Section Head of Cancer Biology at Xenova in the UK and has held a senior staff appointment at the British Columbia Cancer Research Centre. Educated in the United Kingdom, Dr. Chaplin has a B.Sc. in chemistry from the University of Essex, a M.Sc. in pharmacology from the University of Southampton, and completed his Ph.D. in tumor biology at the University of London.
Ms Howson has been a member of the transaction team at JSB partners, a partnering consulting firm specializing in the biotechnology industry. Previously, she served as Executive Vice President of Corporate Development for Lexicon Pharmaceuticals. Prior to Lexicon, she served as Senior Vice President of Corporate and Business Development and was a member of the executive committee at Bristol-Myers Squibb. During her tenure there, Ms. Howson was responsible for leading the company's efforts in external alliances, licensing and acquisitions. Earlier, Ms. Howson served as Senior Vice President and Director of Business Development at SmithKline Beecham. She also managed SR One Ltd., the $100 million venture capital fund of SmithKline Beecham. Ms. Howson has served as an independent business consultant and adviser to companies both in the United States and in Europe. She held the position of Vice President, Venture Investments at Johnston Associates, a venture capital firm, and earlier as Director of Worldwide Business Development and Licensing for Squibb Corporation.
Ms. Howson currently serves on the boards of Idenix Pharmaceuticals, Inc. (Nasdaq:IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, and S*Bio Pte Ltd. She also serves as a consultant to Pitango Venture Fund and is a member of the advisory board to Triana Venture Partners. She previously served on the boards of Ariad Pharmaceuticals, SkyePharma, NPS Pharma, Targacept, and HBA. Ms. Howson received her M.B.A. in finance and international business from Columbia University. Educated as a chemical engineer, she holds a M.S. from the City College of New York and a B.S. from the Technion in Israel.
Gerald McMahon Ph.D
Dr. McMahon is Senior Vice President and Oncology Innovative Medicines Unit Leader of Medimmune LLC, a wholly owned subsidiary of Astra Zeneca PLC, a position which he has held since 2010. Dr. McMahon served as the Chief Executive Officer of Poniard Pharmaceuticals, Inc. from May 2004 to February 2010 and as the Chairman of the Board of Directors of Poniard from May 2004 to May 2011. He was a Venture Partner at Bay City Capital, LLC from February 2010 to October 2010. Dr. McMahon has spent more than 20 years as a business executive in the healthcare and biotech industries where he held various roles at Pfizer, Pharmacia, and Sandoz. In addition, Dr. McMahon was employed 10 years at SUGEN where he was instrumental to build the business leading to the successful discovery, development, and regulatory approvals of novel oncology drugs. Since his role as President of SUGEN in 2003, he served as a Venture Partner with Bay City Capital and also has served as CEO and in various board of director roles for public and private healthcare companies. Dr. McMahon holds a B.S. in biology and earned a Ph.D. in 1980 in biochemistry from Rensselaer Polytechnic Institute and held post-graduate appointments at Tufts Medical School in Boston and the Massachusetts Institute of Technology in Cambridge, Massachusetts.
William D. Schwieterman M.D.
Dr. Schwieterman has been an independent consultant to biotech and pharmaceutical companies specializing in clinical development since July 2002. Dr. Schwieterman is a board-certified internist and a rheumatologist who was formerly Chief of the Medicine Branch and Chief of the Immunology and Infectious Disease Branch in the Division of Clinical Trials at the FDA. In these capacities and others, Dr. Schwieterman spent 10 years at the FDA in the Center for Biologics overseeing a wide range of clinical development plans for a large number of different types of molecules. Dr. Schwieterman holds a B.S. and M.D. from the University of Cincinnati.